Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome

Authors

  • T. Hugh JONES

    1. Academic Unit of Diabetes, Endocrinology & Metabolism, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, and Robert Hague Centre for Diabetes & Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK
    Search for more papers by this author

T. Hugh Jones, Robert Hague Centre for Diabetes & Endocrinology,
Barnsley Hospital NHS Foundation Trust, Barnsley, S75 2EP, UK.
Tel: +44 1226 432147
Fax: +44 1226 434404
Email: hugh.jones@nhs.net

Abstract

Observations from clinical studies suggest that low serum levels of testosterone in men are often associated with obesity, insulin resistance, and metabolic compromise. Indeed, the clinical symptoms of late-onset hypogonadism are markedly similar to those of Type 2 diabetes mellitus (T2DM) and metabolic syndrome, and may share a similar pathophysiology. Observational and experimental data suggest that testosterone treatment improves a number of hallmark features of T2DM and metabolic syndrome, namely insulin resistance, obesity, dyslipidemia, and sexual dysfunction. Consequently, clinical studies have been undertaken to assess the impact of testosterone-replacement therapy in this patient group. The present article reviews the observational clinical data suggesting an association between low serum testosterone and metabolic impairment, the clinical data relating to the effects of testosterone treatment on components of the metabolic syndrome, and the randomized clinical trails that have formally investigated whether testosterone-replacement therapy provides clinical benefit to hypogonadal men with T2DM and/or metabolic syndrome.

Ancillary